Mezigdomide Enhances Activity of BCMA-Targeted Cellular and T-Cell Engager Therapies and Mitigates Immune Toxicity in Preclinical Models of Multiple Myeloma

被引：0

作者：

Larrayoz, Marta ^{[1
]}

Bjorklund, Chad Chad ^{[2
]}

Jimenez, Maddalen ^{[1
]}

Lozano, Teresa ^{[3
]}

Sanz, Sonia ^{[1
]}

Arriazu, Elena ^{[1
]}

Zon, Rebecca ^{[4
]}

Rodriguez-Madoz, Juan Roberto ^{[5
]}

Paiva, Bruno ^{[6
]}

Rodriguez-Otero, Paula ^{[7
]}

San-Miguel, Jesus ^{[7
]}

Prosper, Felipe ^{[8
]}

Jose Lasarte, Juan ^{[3
]}

Ebert, Benjamin ^{[4
]}

Hagner, Patrick ^{[2
]}

Martinez-Climent, Jose Angel ^{[1
]}

机构：

[1] Univ Navarra, Dept Hematol, Ctr Appl Med Res, Clin Univ Navarra Canc Ctr,CIBERONC,IDISNA, Pamplona, Spain

[2] Bristol Myers Squibb, New York, NY USA

[3] CIMA Univ Navarre, Inst Hlth Res Navarra IdiSNA, Pamplona, Spain

[4] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[5] Canc Ctr Univ Navarra CCUN, Pamplona, Spain

[6] Univ Navarra, Canc Ctr Clin, Pamplona, Spain

[7] Clin Univ Navarra, Pamplona, Spain

[8] CIBERONC, Hematol & Cell Therapy Serv, CCUN Hematol & Oncol Program, Clin Univ Navarra IdISNA,Ctr Appl Med Res CIMA, Madrid, Spain

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA-09

引用

页码：S6 / S7

页数：2